This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Subacute sclerosing panencephalitis (SSPE) is a progressive encephalopathy with fatal outcome affecting children and young adults and is caused by the persistent infection of an altered form of the measles virus. Beneficial therapy for SSPE has not yet been developed, but immunomodulators such as α- and β-interferon (IFN) or isoprinosine are promising. The intraventricular administration of α-IFN in combination with oral isoprinosine is currently the most effective treatment, resulting in the stabilization and improvement of the neurologic disability in 30% of patients treated.1–3⇓⇓ In all these cases, α-IFN was delivered through a catheter inserted into the lateral ventricle and connected to an Ommaya reservoir placed under the scalp. Infection is the most common complication of the Ommaya reservoir, and meningitis and meningoencephalitis were reported in 2 to 23% of …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
- Improvement of SSPE by intrathecal infusion of alpha-IFN
- Reply to Wirguin et al
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Topics Discussed
Alert Me
Recommended articles
Intrathecal administration of recombinant human superoxide dismutase 1 in amyotrophic lateral sclerosis: A preliminary safety and pharmacokinetic study
Improvement of SSPE by intrathecal infusion of α-IFN
Intrathecal treatment trial of rituximab in progressive MS
Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis